Brief: 60 Degrees Pharma Announces Type C Meeting With FDA To Discuss Development Of Tafenoquine For Babesiosis, An Emerging Tick-Borne Disease
15/11/2023 12:30
Nov 15 (Reuters) - 60 Degrees Pharmaceuticals Inc
SXTP.O :
* 60 DEGREES PHARMA ANNOUNCES TYPE C MEETING WITH FDA TO
DISCUSS
DEVELOPMENT OF TAFENOQUINE FOR BABESIOSIS, AN EMERGING
TICK-BORNE DISEASE
* 60 DEGREES PHARMACEUTICALS INC - MEETING WITH FDA
SCHEDULED FOR
JANUARY 15, 2024
Source text for Eikon: ID:nGNX3l1D6J
Further company coverage: SXTP.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on 60 Degrees Pharmaceuticals
See all newsBrief: 60 Degrees Pharmaceuticals Says May Submit NDA For Tafenoquine To FDA Before End Of Q1 2028 - SEC Filing
U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, NVIDIA
Brief: 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (Ndin) With FDA For Australian Chestnut Extract
NASDAQ RESUMED AT 10:06 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM